Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.63 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431813 | 0.93 | F10 (0.72) | F10KCNH2KLKB1 | |
| SCHEMBL6215501 | 0.93 | F10 (0.70) | F10KCNH2KLKB1 | |
| SCHEMBL2438964 | 0.88 | F10 (0.75) | F10KCNH2KLKB1F2 | |
| SCHEMBL2439110 | 0.88 | F10 (0.72) | F10 | |
| SCHEMBL6219022 | 0.85 | F10 (0.70) | F10KCNH2KLKB1 | |
| SCHEMBL2433780 | 0.85 | F10 (0.73) | F10KCNH2KLKB1 | |
| SCHEMBL799840 | 0.85 | F10 (1.00) | F10KCNH2F2 | |
| SCHEMBL6105601 | 0.83 | F10 (0.70) | F10KCNH2KLKB1 | |
| SCHEMBL2431134 | 0.82 | F10 (1.00) | F10KCNH2KLKB1F2 | |
| SCHEMBL6218521 | 0.82 | F10 (0.63) | F10KCNH2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542529-B1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | LLC PHARMADIALL (RU) | 2019-09-04 | — | — | EP | disclosed |
| US-9708265-B2 | Urethanes, ureas, amidines and related inhibitors of factor Xa | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2017-07-18 | — | — | US | disclosed |
| EP-2542529-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | Tovbin, Dmitry Gennadievich (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2013-01-03 | — | — | US | disclosed |
| WO-2011108963-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | TOVBIN DMITRY GENNADIEVICH (RU) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PLAUR, PLAU, UTS2R | F10 9/4885KCNH2 1486/4885KLKB1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.